Enterprise Value
61.6M
Cash
89.48M
Avg Qtr Burn
-10.36M
Short % of Float
0.75%
Insider Ownership
0.69%
Institutional Own.
59.60%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CARDAMYST (Etripamil) (calcium channel blocker) Details Paroxysmal supraventricular tachycardia | PDUFA Approval decision | |
Etripamil (calcium channel blocker) Details Atrial fibrillation | Phase 2 Data readout | |
Etripamil (calcium channel blocker) Details Angina, Coronary artery disease | Failed Discontinued |